生物检定

气相色谱法测定人类乳头瘤病毒疫苗中MPL含量*

展开
  • 中国食品药品检定研究院 卫生部生物技术产品检定及标准化重点实验室,北京 102629
第一作者 路琼 Tel:(010)53851697;E-mail:luqiong@nifdc.org.cn
聂玲玲 Tel:(010)53851703;E-mail:nielingling@nifdc.org.cn
** Tel:(010)53851737;E-mail:huangweijin@nifdc.org.cn

修回日期: 2022-05-11

  网络出版日期: 2024-06-24

基金资助

* 面上基金32070678;国家科技重大专项“创新生物技术药物评价及标准化关键技术研究2018zx09101001

Determination of MPL content in HPV vaccines by gas chromatography*

Expand
  • National Institutes for Food and Drug Control, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Beijing 102629, China

Revised date: 2022-05-11

  Online published: 2024-06-24

摘要

目的:建立用气相色谱法测定人类乳头瘤病毒(HPV)疫苗中3-O-脱酰基-4'-单磷酰脂质A(MPL)的含量。方法:HPV疫苗中的MPL经过与氢氧化钠-甲醇的皂化反应,以己烷进行萃取,以三氟醋酐进行衍生化,再经HP-5色谱柱(30 m×0.32 mm,0.25 μm)分离,火焰离子检测器(FID)检测,用MPL对照品和内标十五烷酸(pentadecanoic acid)进行内标法定量测定HPV疫苗中MPL含量。结果:MPL质量浓度在15~150 μg·mL-1范围内线性关系良好(r=0.999),精密度RSD为0.24%,重复性RSD为1.0%,稳定性RSD为0.37%,平均回收率为100.1%~100.5%(RSD小于2.0%)。12个批次的HPV疫苗中MPL含量范围为93.4~103.2 μg·mL-1,符合质控要求。结论:本法准确可靠,特异性强,可对HPV疫苗中MPL进行检测。

本文引用格式

路琼, 聂玲玲, 聂建辉, 赵晨燕, 张黎, 王萌, 黄维金, 王佑春 . 气相色谱法测定人类乳头瘤病毒疫苗中MPL含量*[J]. 药物分析杂志, 2022 , 42(7) : 1137 -1141 . DOI: 10.16155/j.0254-1793.2022.07.05

Abstract

Objective: To establish an analytical method for detection the content of 3-O-deacyl-4'-monophosphoryl lipid A(MPL) adjuvant from human papillomavirus(HPV) vaccine with gas chromatography. Methods: After saponified with sodium hydroxide, extracted in hexane and derivated by trifluoroacetic anhydride, the target components were separated by HP-5 column(30 m×0.32 mm, 0.25 μm) and detected using gas chromatography-flame ionization detector(GAS-FID) and quantified by MPL standard material with the help of an internal standard pentadecanoic acid. Results: The linear relationship was good in the range of 15-150 μg·mL-1 with good linearity(r=0.999). The RSDs of precision, reproducibility and stability were 0.24%, 1.0% and 0.37% separately. The average recovery rates were in the ranges of 100.1%-100.5%, with RSD less than 2.0%.The MPL contents of 12 batches vaccines were tested in the range of 93.4-103.2 μg·mL-1, which meets the specification. Conclusion: This accurate and specific method can be applied to the MPL detection in vaccine.

参考文献

[1] SHAH RR, HASSETT KJ, BRITO LA. Overview of vaccine adjuvants: introduction, history, and current status[J].Methods Mol Biol, 2017, 1494: 1
[2] YOUNG AJ. Adjuvants: what a difference 15 years makes![J].Vet Clin North Am Food Anim Pract, 2019, 35(3): 391
[3] GARCON N. Preclinical development of AS04[J].Methods Mol Biol, 2010, 626: 15
[4] CASELLA CR, MITCHELL TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant[J].Cell Mol Life Sci,2008, 65(20): 3231
[5] MATA-HARO V, CEKIC C, MARTIN M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4[J].Science, 2007, 316(5831): 1628
[6] GARCON N, VAN MECHELEN M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems[J].Expert Rev Vaccines, 2011, 10(4): 471
[7] FOCHESATO M, DENDOUGA N, BOXUS M. Comparative preclinical evaluation of AS01 versus other adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine[J].Hum Vaccin Immunother, 2016, 12(8): 2092
[8] GIANNINI SL, HANON E, MORIS P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only[J].Vaccine, 2006, 24(33-34): 5937
[9] DIDIERLAURENT AM, MOREL S, LOCKMAN L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity[J].J Immunol, 2009, 183(10): 6186
[10] SANDGREN KJ, TRUONG NR, SMITH JB, et al. Vaccines for herpes simplex: recent progress driven by viral and adjuvant immunology[J].Methods Mol Biol, 2020, 2060: 31
[11] BRITO LA, MALYALA P, O'HAGAN DT. Vaccine adjuvant formulations: a pharmaceutical perspective[J].Semin Immunol, 2013, 25(2): 130
[12] 王明娟, 王琰, 胡昌勤. HPLC-ELSD法测定BLP25脂质体疫苗中MPL的含量[J].中国药事, 2012, 26(5): 478
WANG MJ,WANG Y,HU CQ. Determination of MPL content in BLP25 liposome vaccine by HPLC-ELSD[J].Chin Pharm Aff, 2012, 26(5): 478
[13] ABEL K, DESCHMERTZING H, PETERSON JI. Classification of microorganisms by analysis of chemical composition. i. feasibility of utilizing gas chromatography[J].J Bacteriol, 1963, 85(5): 1039
[14] 宋红梅,李波,李丽婕. 气相色谱法分析沙门氏菌脂肪酸组成的研究[J].现代预防医学, 2009, 36(22): 4324
SONG HM, LI B, LI LJ. Study on the cellular fatty acids composition of salmonella by unqualification rates analysis[J].Mod Prev Med, 2009, 36(22): 4324
[15] 李宏涛. 气相色谱法快速测定大豆油中脂肪酸含量[J].药物分析杂志, 1995, 15(6): 27
LI HT. The rapid determination of fatty acids in soybean oil by gas chromatography[J].Chin J Pharm Anal, 1995, 15(6): 27
[16] VEYS A, CALLEWAERT W, WAELKENS E, et al. Application of gas-liquid chromatography to the routine identification of nonfermenting gram-negative bacteria in clinical specimens[J].J Clin Microbiol, 1989, 27(7): 1538
[17] LUGOWSKI C, ROMANOWSKA E. Chemical studies on Shigella sonnei lipid A[J].Eur J Biochem, 1974, 48(2): 319
[18] DA COSTA MS, ALBUQUERQUE L, NOBRE MF, et al. The identification of fatty acids in bacteria[J].Methods Microbiol, 2011, 38: 183
[19] HIROSHI O, KAZUO K. Grouping of pseudomonas species on the basis of cellular fatty acid composition and the quinone system with special reference to 3-hydroxy fatty acids[J].J Gen Appl Microbiol, 2006, 29(1): 17
[20] OSTERHOUT GJ, SHULL VH, DICK JD. Identification of clinical isolates of gram-negative nonfermentative bacteria by an automated cellular fatty acid identification system[J].J Clin Microbiol, 1991, 29(9): 1822
文章导航

/